Compare SXT & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXT | ACLX |
|---|---|---|
| Founded | 1882 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.2B |
| IPO Year | N/A | 2022 |
| Metric | SXT | ACLX |
|---|---|---|
| Price | $90.68 | $75.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $110.00 | ★ $115.50 |
| AVG Volume (30 Days) | 283.7K | ★ 1.2M |
| Earning Date | 10-31-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ 56.32 | N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $1,595,084,000.00 | $35,898,000.00 |
| Revenue This Year | $4.80 | N/A |
| Revenue Next Year | $5.94 | $302.49 |
| P/E Ratio | $28.25 | ★ N/A |
| Revenue Growth | ★ 4.25 | N/A |
| 52 Week Low | $66.15 | $47.86 |
| 52 Week High | $121.54 | $94.07 |
| Indicator | SXT | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.75 | 40.59 |
| Support Level | $92.41 | $66.00 |
| Resistance Level | $96.77 | $75.03 |
| Average True Range (ATR) | 2.30 | 5.47 |
| MACD | -0.36 | -1.18 |
| Stochastic Oscillator | 0.46 | 27.20 |
Sensient Technologies Corp manufactures and markets natural and synthetic colors, flavors, and other specialty ingredients. Sensient's offerings are predominantly applied to consumer-facing products, including food and beverage, cosmetics and pharmaceuticals, nutraceuticals, and personal care industries. Its principal products are flavors, flavor enhancers, ingredients, extracts, and bionutrients, essential oils, dehydrated vegetables and other food ingredients, natural and synthetic food and beverage colors, and others. The company's reportable segments are; Flavors & Extracts, which derive key revenue, Color, Asia Pacific, and Corporate and Other. Geographically, the company generates maximum revenue from North America, followed by Europe, Asia-Pacific, and other regions.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.